Under the Symbol:
WEED, Inc. Acquires WEED(R) Trademarks
Thursday, October 18, 2018 11:55 AM
Acquisition of the Trademarks Part of the Company's Plan to Acquire Intellectual Property Relevant to the Industry when Practical
TUCSON, AZ / ACCESSWIRE / October 18, 2018 / WEED, Inc. (OTCQB: BUDZ), a global Cannabis holding company focused on the development and application of cannabis–derived compounds for the treatment of human diseases, announced today that it has acquired the rights to two trademark registrations directed to the name of the company, WEED.
The marks, which were acquired by WEED, Inc. from Copalix (PTY) Ltd., a private South African company, were assigned in the United States Patent Office and European Union Intellectual Property Office, respectively, on May 29 and August 14 of this year. The acquisitions include the purchase of a United States Trademark Registration (U.S. Trademark Registration No. 4,927,872) for the wordmark "WEED®" for pouches for carrying electronic cigarettes, mouth pieces for electronic cigarettes, and wicks for electronic cigarettes and a European Trademark Registration (European Community Trademark Registration No. 11953387) for the same wordmark "WEED®" for batteries and electronic accumulators, batteries for electronic cigarettes, chargers for electric cigarettes, battery chargers for electron cigarettes, USB chargers, car chargers, parts and fittings for the aforesaid goods and matches, pouches for carrying electronic cigarettes, mouth pieces for electronic cigarettes, rechargeable cigarette cases along with their parts and fittings.
The purchases are part of a broader effort by WEED, Inc. to expand its Intellectual Property (IP) Brands Division into a variety of goods and services outside those offered as part of its core goods and services, namely, the development of cannabis–derived healthcare & adult use Cannabis products. Among other measures, WEED, Inc. has sought to expand WEED™ and other associated brands including WEED RULES!™ to goods and services that include cosmetics and cleaning preparations, paper goods and printed matter, and natural agricultural products in addition to others through the filing of multiple trademark applications in the United States Patent and Trademark Office. "We are hopeful that such actions to protect existing rights and acquire future intellectual property rights will fortify WEED, Inc.'s position as a leader in the cannabis industry, creating shareholder value above and beyond the the value created by the company's core business," comments WEED, Inc. President/CEO Glenn E. Martin. "We believe the majority of discoveries in Cannabis are yet to be found. I believe these exciting times will not only change global health but the penetrate many markets worldwide! WEED'S leading scientists are already working on new breeding programs, genetic modifications, formulations and drug delivery systems for both humans and pets."
About WEED, Inc.
WEED, Inc. along with its subsidiary, Sangro AT, LLC, is an early stage cannabis holding company, which focuses on the development and application of cannabis-derived compounds for the treatment of human disease with a goal of identifying, collecting, and archiving a collection of medicinal cannabis strains. It also focuses on purchasing land and building commercial grade cultivation centers to consult, assist, manage, and lease to dispensary owners and organic grow operators. WEED, Inc. is based out of Tucson, Arizona and more information can be found on the corporation's website at www.WEEDInc.co.
About Sangre AT, LLC
Sangre AT, LLC (dba "Sangre AgroTech") is WEED, Inc.'s wholly-owned subsidiary and is a plant genomic research and breeding company comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available. For additional information about Sangre AgroTech, please visit www.sangreagrotech.com.
This release contains forward-looking statements. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business, including that we have a limited operating history and very limited funds, are dependent upon key personnel whose loss may adversely impact our business, some of our potential business activities, while believed to be compliant with applicable state law, may be illegal under federal law because they violate the Federal Controlled Substances Act, and we may be subject to the risks related to the cost, delays and uncertainties associated with potential future scientific research, product development, clinical trials and the regulatory approval process. We may not be able to enter into binding agreements related to the subject matter of this press release on terms favorable to us or at all. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
For more information, contact:
Glenn E. Martin at (520) 818-8582 or [email protected]
SOURCE: WEED, Inc.